Compare New York Times Co (NYT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Repligen Corporation Common Stock — how do they compare? New York Times Co trades at $67.13 (market cap $10.83B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: New York Times Co and Repligen Corporation Common Stock are close in size by market cap, and New York Times Co pays a 1.37% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 82 Days and Repligen Corporation Common Stock for 0 Days on average.
| NYT | RGEN | |
|---|---|---|
Market Cap | $10.83B | $11.31B |
Volume | 1,004,378 | 1,216,919 |
Sector | Media | Health |
52-Week High | $85.86 | $194.57 |
52-Week Low | $54.86 | $102.87 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $10.22B | $11.20B |
Dividend Yield | 1.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.88, up 1.21% today, with a bearish technical signal but strong fundamental performance. Revenue grew to $2.82B in 2025 with a net income margin of 12.17%, and the company has beaten EPS estimates for three consecutive quarters. A recent shareholder lawsuit alleging bias in reporting and the ongoing AI copyright case with OpenAI are key news items.
The outlook is mixed: solid earnings growth and a consensus price target of $81.50 suggest upside, but legal risks and a bearish technical picture near-term pose challenges. The stock offers a dividend yield supported by positive cash flow, yet investor sentiment is cautious amid litigation concerns.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
